EPA has published its May 2026 TSCA Section 5 statements of findings for certain new-chemical and significant-new-use submissions determined not likely to present an unreasonable risk under the reviewed conditions of use. The notice is not a new medical-device restriction, but it can be useful upstream intelligence when suppliers introduce new polymers, additives, coatings, or other chemical inputs.
FDA has formally published Recognition List 066 in the Federal Register, covering additions, replacements, and revisions to recognized consensus standards used in medical-device premarket submissions. Manufacturers should review not only the new standard editions but also FDA recognition numbers, complete versus partial recognition, and transition deadlines for declarations of conformity.
Eight selected FDA Class II recall events for 16–22 August 2026 highlight neonatal breathing-circuit failures, erroneous diagnostic results, software-driven measurement and analyzer risks, an implant machining defect, endotoxin-related surgical-kit actions, a CT bolus-tracking issue, and high-volume urostomy pouch leakage. The issue emphasizes clinical follow-up, inventory control, result review, software correction, and component-level quality management.
Device Recalls · FDA Class II Recall Watch: 16–22 August 2026 ·
These circuits support neonatal and infant respiratory care, so a connector failure can create both immediate clinical-management needs and broad inventory work. The recall also illustrates how one failure mode may span several FDA product classifications and catalog families while still representing a single underlying field action.
Device Recalls · FDA Class II Recall Watch: 16–22 August 2026 ·
The defect is notable because a software import can silently change laboratory calculation logic rather than producing an obvious system failure. Laboratories determine whether predefined rules were modified and whether results need retrospective review.
Device Recalls · FDA Class II Recall Watch: 16–22 August 2026 ·
A machining nonconformance in an implant component can become consequential at the point of surgery, where proper screw engagement is part of fixation. The response also requires removal of affected unused product from implant sets and consignment inventory, making traceability and inventory control important beyond the manufacturing site.
Device Recalls · FDA Class II Recall Watch: 16–22 August 2026 ·
Measurement errors in a diagnostic imaging workstation can affect interpretation even when source images remain available. The mitigation combines retrospective study identification, cross-checking against modality measurements, and a software update.
Device Recalls · FDA Class II Recall Watch: 16–22 August 2026 ·
The event shows how one component-level nonconformance can propagate into many finished surgical-kit configurations and product classifications. For hospitals and manufacturers, the response depends on tracing affected kits, quarantining inventory, applying warning over-labels, removing the affected component before kit use, and notifying downstream customers when products were redistributed.
Device Recalls · FDA Class II Recall Watch: 16–22 August 2026 ·
Bolus Tracking coordinates contrast enhancement with CT image acquisition, so failure to trigger the clinical scan can disrupt an imaging workflow at a critical step. The event also demonstrates a software correction handled under radiation-product requirements, making it relevant to both imaging-service operations and regulatory teams responsible for radiological systems.
Device Recalls · FDA Class II Recall Watch: 16–22 August 2026 ·
The underlying failure is comparatively simple, but the large quantity and broad distribution create substantial inventory and replacement work. The defect requires coordinated field action and downstream notification.
FDA has classified the recall of certain Medline convenience kits containing B. Braun bupivacaine hydrochloride components as Class I. Medline Industries, LP is correcting affected kits because they include Huons Bupivacaine Hydrochloride in Dextrose Injection, USP that was recalled for quality issues.
FDA’s general draft guidance on Predetermined Change Control Plans remains in draft status, but section 515C of the FD&C Act is already in effect and manufacturers may submit PCCPs today. The draft explains what planned device modifications may be appropriate for a PCCP and the information FDA expects manufacturers to provide.
FDA has issued a discussion paper seeking feedback on how generative AI-enabled medical devices should be assessed across risk classification, premarket evaluation, and postmarket monitoring. The paper outlines possible approaches including a two-axis risk framework and competency-based premarket assessment, but it does not establish new regulatory requirements.
FDA has classified the recall of specified BD Intraosseous Vascular Access System Needle Set lots as Class I after out-of-tolerance dimensions were linked to difficulty removing the obturator and potential delays in therapy; the FDA recall database lists Bard Access Systems, Inc. as the recalling firm.
Eight selected FDA Class II recall events for 9–15 August 2026 highlight diagnostic false negatives, interventional imaging software failures, a potential sterilization underdose, endotoxin-related kit actions, reagent rework, cryosurgical pressure risk, and an incorrect guidewire. The issue centers on clinically meaningful failures plus substantial inventory, notification, correction, and replacement work.
Device Recalls · FDA Class II Recall Watch: 9–15 August 2026 ·
False-negative molecular respiratory results can directly affect diagnostic decision-making, making this recall particularly relevant to laboratories and IVD manufacturers. The failure also shows how a reagent-manufacturing error can escape normal controls while control assays still pass, creating a significant result-integrity and quality-system lesson.
Device Recalls · FDA Class II Recall Watch: 9–15 August 2026 ·
Azurion systems support image-guided interventional procedures, so software failures affecting both imaging and equipment movement can create immediate procedural and workflow consequences. Grouping the two FDA records also illustrates why product-version records with substantially identical failure modes and corrective instructions should be treated as one editorial event.
Device Recalls · FDA Class II Recall Watch: 9–15 August 2026 ·
A potential sterilization underdose in products used to administer fluids into the vascular system has direct clinical and operational significance. The event also creates broad inventory work because facilities must locate specified lots across storage and use locations, discontinue affected product, and manage destruction, quarantine, replacement, and downstream notification.
Device Recalls · FDA Class II Recall Watch: 9–15 August 2026 ·
This event shows how one supplier-component problem can propagate across many finished procedural kits and generate multiple FDA records. For hospitals and supply-chain teams, the operational burden extends beyond a single SKU because affected components must be identified inside kits, clinicians notified, warning labels applied, and downstream customers addressed.
Device Recalls · FDA Class II Recall Watch: 9–15 August 2026 ·
This recall connects a manufacturing-process deviation directly to the reliability of a diagnostic result used in acute kidney injury assessment. It is relevant to IVD quality teams because the FDA record links the non-validated rework to potential downstream diagnostic, treatment, and monitoring consequences rather than a purely administrative nonconformity.
Device Recalls · FDA Class II Recall Watch: 9–15 August 2026 ·
The event combines a physical device-design hazard with a software field correction, making it relevant to both hardware and software quality teams. Its nationwide scope and representative-installed software also create operational work for facilities while the FDA record permits continued use under existing warnings and instructions until correction.
Device Recalls · FDA Class II Recall Watch: 9–15 August 2026 ·
Loss of geometry movement in an interventional fluoroscopic system can disrupt procedure workflow even when imaging remains available. The event is relevant to hospitals because the permanent correction is a future software installation, requiring users to retain and post interim instructions, recognize the failure mode, and use the specified restart process meanwhile.
Device Recalls · FDA Class II Recall Watch: 9–15 August 2026 ·
An incorrect component inside a procedure kit can create a mismatch at the point of use even when the outer product identity appears correct. The event is relevant to vascular-device manufacturers and hospitals because it illustrates the importance of kit-component verification, inventory isolation, and downstream traceability for distributed procedural products.